miRNAs as potential game-changers in renal cell carcinoma: Future clinical and medicinal uses

Elballal, Mohammed S.; Sallam, Al-Aliaa M.; Elesawy, Ahmed E.; Shahin, Reem K.; Midan, Heba M.; Elrebehy, Mahmoud A.; Elazazy, Ola; El-Boghdady, Rawnaa Mohammed; Blasy, Shaimaa Hassan; Amer, Nada Mahmoud; Farid, Hadeer Ibrahim; Mohammed, Dina Ashraf; Ahmed, Shaymaa Adly; Mohamed, Sally Samir; Doghish, Ahmed S.

doi:10.1016/j.prp.2023.154439

Cited by 50 publications

(1 citation statement)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LncRNAs are arranged in secondary and three-dimensional structures so they can function as RNA and or protein [5]. The identification of non-coding RNA, such as long non-coding RNA (lncRNA) and microRNA (miRNA), in the advancement of human diseases has broadened to encompass potential connections with various conditions [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

The clinical significance of long non-coding RNAs MALAT1 and CASC2 in the diagnosis of HCV-related hepatocellular carcinoma

Golam,

Khalil,

Shaker

et al. 2024

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background Globally, hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death due to a lack of early predictive and/or diagnostic tools. Thus, research for a new biomarker is important. LncRNAs play a functional role in target gene regulation and their deregulation is associated with several pathological conditions including HCC. Objective This study aimed to explore the diagnostic potential of two LncRNAs MALAT1 and CASC2 in HCC compared to the routinely used diagnostic biomarker. Materials and methods The current study is a case-control study carried out at Fayoum University Hospital and conducted on 89 individuals. The study included three groups of 36 HCC patients on top of HCV(HCC/HCV), 33 HCV patients, and 20 healthy volunteers as a control group. All study subjects were subjected to radiological examinations. The determination of CBC was performed by the automated counter and liver function tests by the enzymatic method were performed. In addition, HCV RNA quantification and the expression level of two LncRNAs (MALAT1 and CASC2) were performed by qRT-PCR. Results The results revealed a statistically significant difference between study groups regarding liver function tests with a higher mean in HCC/HCV group. Also, serum MALAT1 significantly up-regulated in HCV (11.2±2.8) and HCC/HCV (4.56±1.4) compared to the control group. Besides, serum CASC2 levels in the HCV group were significantly upregulated (14.9±3.6), while, downregulated in the HCC group (0.16± 0.03). Furthermore, The ROC analysis for diagnostic efficacy parameters indicated that CASC2 has higher accuracy (94.6%) and sensitivity (97.2%) for HCC diagnosis than AFP with an accuracy of (90.9%), sensitivity (69.4%), and MALAT1 showed an accuracy of (56.9%), sensitivity (72.2%). Conclusion Our study results indicated that CASC2 is a promising biomarker and is considered better and could help in HCC diagnosis on top of HCV than MALAT1 and the routine biomarker AFP.

show abstract